Conjugates of a GLP-1 moiety may be covalently attached to one or more water-soluble polymers. For instance, a GLP-1 polymer conjugate may include a GLP-1 moiety releasably attached at its N-terminus to a water-soluble polymer. The GLP-1 polymer conjugate may include a GLP-1 moiety covalently attached to a water-soluble polymer, wherein the GLP-1 moiety possesses an N-methyl substituent.
Solution Phase Processes for the Manufacture of Macrocyclic Depsipeptides and New Intermediates
申请人:ACEMOGLU Murat
公开号:US20150218224A1
公开(公告)日:2015-08-06
The invention relates to a method or process for solution phase chemical manufacture of depsipeptides of the formula I,
wherein the symbols have the meaning defined in the description, to new intermediates and their manufacture, as well as related invention embodiments.
The invention provides peptides that are chemically modified by covalent attachment of a water-soluble oligomer. A conjugate of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from the characteristics of the peptide not attached to the water-soluble oligomer.
CONJUGATES OF A GM-CSF MOIETY AND A POLYMER
申请人:NEKTAR THERAPEUTICS
公开号:US20140044672A1
公开(公告)日:2014-02-13
Conjugates of a GM-CSF moiety and one or more water-soluble polymers are provided. Typically, the water-soluble polymer is poly(ethylene glycol) or a derivative thereof. Also provided are compositions comprising conjugates, methods of making conjugates, and methods of administering compositions comprising conjugates to a patient.